Home Newsfeeds RBC Capital Reiterates Outperform on Design Therapeutics, Maintains $24 Price Target

RBC Capital Reiterates Outperform on Design Therapeutics, Maintains $24 Price Target

RBC Capital analyst Leonid Timashev reiterates Design Therapeutics (NASDAQ:DSGN) with a Outperform and maintains $24 price target.

byBenzinga Newsdesk

March 15, 2023

1 minute read

RBC Capital analyst Leonid Timashev reiterates Design Therapeutics (NASDAQ:DSGN) with a Outperform and maintains $24 price target.

Cannabis Brand Yummi Karma Partners With Nabis For Exclusive Distribution

By Vuk Zdinjak

January 5, 12:55 PM

Yummi Karma, has officially partnered with wholesale platform, Nabis, to expand distribution of its bestselling tinctures.

GRAMF

B. Riley Securities Maintains Buy on Synchronoss Technologies, Lowers Price Target to $2

By Benzinga Newsdesk

March 8, 10:32 AM

B. Riley Securities analyst Josh Nichols maintains Synchronoss Technologies (NASDAQ:SNCR) with a Buy and lowers the price target from $2.75 to $2.

SNCR

i-80 Announces CAD$32M Private Placement Of 11,852,000 Shares Of Common Stock At A Price Of CAD$2.70/Share

By Benzinga Newsdesk

July 18, 4:46 PM

i-80 GOLD CORP. (TSX:IAU) (NYSE:IAUX) ("i-80", or the "Company"), is pleased to announce that it has entered into an agreement with CIBC Capital Markets as lead underwriter and sole bookrunner on behalf of a syndicate of

IAUX

Barclays Maintains Underweight on Acadia Healthcare Co, Raises Price Target to $85

By Benzinga Newsdesk

July 29, 8:41 AM

Barclays analyst Sarah James maintains Acadia Healthcare Co (NASDAQ:ACHC) with a Underweight and raises the price target from $75 to $85.

ACHC

RBC Capital Reiterates Outperform on Design Therapeutics, Maintains $24 Price Target

Related Posts

Cannabis Brand Yummi Karma Partners With Nabis For Exclusive Distribution

B. Riley Securities Maintains Buy on Synchronoss Technologies, Lowers Price Target to $2

i-80 Announces CAD$32M Private Placement Of 11,852,000 Shares Of Common Stock At A Price Of CAD$2.70/Share

Barclays Maintains Underweight on Acadia Healthcare Co, Raises Price Target to $85